These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

787 related articles for article (PubMed ID: 18302019)

  • 41. Hereditary breast cancer syndromes in a Turkish population. Results of molecular germline analysis.
    Güran S; Ozet A; Dede M; Gille JJ; Yenen MC
    Cancer Genet Cytogenet; 2005 Jul; 160(2):164-8. PubMed ID: 15993273
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases.
    Engert S; Wappenschmidt B; Betz B; Kast K; Kutsche M; Hellebrand H; Goecke TO; Kiechle M; Niederacher D; Schmutzler RK; Meindl A
    Hum Mutat; 2008 Jul; 29(7):948-58. PubMed ID: 18431737
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Heterozygous mutations in the PALB2 hereditary breast cancer predisposition gene impact on the three-dimensional nuclear organization of patient-derived cell lines.
    Wark L; Novak D; Sabbaghian N; Amrein L; Jangamreddy JR; Cheang M; Pouchet C; Aloyz R; Foulkes WD; Mai S; Tischkowitz M
    Genes Chromosomes Cancer; 2013 May; 52(5):480-94. PubMed ID: 23341105
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene.
    Silvestri V; Zelli V; Valentini V; Rizzolo P; Navazio AS; Coppa A; Agata S; Oliani C; Barana D; Castrignanò T; Viel A; Russo A; Tibiletti MG; Zanna I; Masala G; Cortesi L; Manoukian S; Azzollini J; Peissel B; Bonanni B; Peterlongo P; Radice P; Palli D; Giannini G; Chillemi G; Montagna M; Ottini L
    Cancer; 2017 Jan; 123(2):210-218. PubMed ID: 27648926
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BRCA1 and BRCA2 mutations in breast/ovarian cancer patients from central Italy.
    Stuppia L; Di Fulvio P; Aceto G; Pintor S; Veschi S; Gatta V; Colosimo A; Cianchetti E; Cama A; Mariani-Costantini R; Battista P; Palka G
    Hum Mutat; 2003 Aug; 22(2):178-9. PubMed ID: 12872265
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
    Hartikainen JM; Kataja V; Pirskanen M; Arffman A; Ristonmaa U; Vahteristo P; Ryynänen M; Heinonen S; Kosma VM; Mannermaa A
    Clin Genet; 2007 Oct; 72(4):311-20. PubMed ID: 17850627
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses.
    Russo A; Calò V; Agnese V; Bruno L; Corsale S; Augello C; Gargano G; Barbera F; Cascio S; Intrivici C; Rinaldi G; Gulotta G; Macaluso M; Surmacz E; Giordano A; Gebbia N; Bazan V
    Breast Cancer Res Treat; 2007 Nov; 105(3):267-76. PubMed ID: 17221156
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of PALB2/FANCN-associated breast cancer families.
    Tischkowitz M; Xia B; Sabbaghian N; Reis-Filho JS; Hamel N; Li G; van Beers EH; Li L; Khalil T; Quenneville LA; Omeroglu A; Poll A; Lepage P; Wong N; Nederlof PM; Ashworth A; Tonin PN; Narod SA; Livingston DM; Foulkes WD
    Proc Natl Acad Sci U S A; 2007 Apr; 104(16):6788-93. PubMed ID: 17420451
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mutation analysis of BRIP1 in male breast cancer cases: a population-based study in Central Italy.
    Silvestri V; Rizzolo P; Falchetti M; Zanna I; Masala G; Bianchi S; Palli D; Ottini L
    Breast Cancer Res Treat; 2011 Apr; 126(2):539-43. PubMed ID: 21165771
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gross rearrangements in BRCA1 but not BRCA2 play a notable role in predisposition to breast and ovarian cancer in high-risk families of German origin.
    Preisler-Adams S; Schönbuchner I; Fiebig B; Welling B; Dworniczak B; Weber BH
    Cancer Genet Cytogenet; 2006 Jul; 168(1):44-9. PubMed ID: 16772120
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer.
    Lewis AG; Flanagan J; Marsh A; Pupo GM; Mann G; Spurdle AB; Lindeman GJ; Visvader JE; Brown MA; Chenevix-Trench G;
    Breast Cancer Res; 2005; 7(6):R1005-16. PubMed ID: 16280053
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.
    Thomassen M; Hansen TV; Borg A; Lianee HT; Wikman F; Pedersen IS; Bisgaard ML; Nielsen FC; Kruse TA; Gerdes AM
    Acta Oncol; 2008; 47(4):772-7. PubMed ID: 18465347
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Germ-line mutations of the BRCA1 gene in northeastern France].
    Fricker JP; Muller D; Cutuli B; Rodier JF; Janser JC; Jung GM; Mors R; Petit T; Haegele P; Abecassis J
    Bull Cancer; 2000 Oct; 87(10):739-44. PubMed ID: 11084537
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of common PALB2 polymorphisms with breast cancer risk: a case-control study.
    Chen P; Liang J; Wang Z; Zhou X; Chen L; Li M; Xie D; Hu Z; Shen H; Wang H
    Clin Cancer Res; 2008 Sep; 14(18):5931-7. PubMed ID: 18794107
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Contributions of ATM mutations to familial breast and ovarian cancer.
    Thorstenson YR; Roxas A; Kroiss R; Jenkins MA; Yu KM; Bachrich T; Muhr D; Wayne TL; Chu G; Davis RW; Wagner TM; Oefner PJ
    Cancer Res; 2003 Jun; 63(12):3325-33. PubMed ID: 12810666
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
    Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
    Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mutational analysis of BRCA2 in Spanish breast cancer patients from Castilla-Leon: identification of four novel truncating mutations.
    Duran M; Esteban-Cardeñosa E; Velasco E; Infante M; Miner C
    Hum Mutat; 2003 Apr; 21(4):448. PubMed ID: 12655567
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
    Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
    Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Germline PALB2 mutation analysis in breast-pancreas cancer families.
    Stadler ZK; Salo-Mullen E; Sabbaghian N; Simon JA; Zhang L; Olson SH; Kurtz R; Offit K; Foulkes WD; Robson ME; Tischkowitz M
    J Med Genet; 2011 Aug; 48(8):523-5. PubMed ID: 21415078
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of a novel BRCA1 large genomic rearrangement in a Spanish breast/ovarian cancer family.
    Palanca Suela S; Esteban Cardeñosa E; Barragán González E; Oltra Soler S; de Juan Jiménez I; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E; Bolufer Gilabert P;
    Breast Cancer Res Treat; 2008 Nov; 112(1):63-7. PubMed ID: 18060491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.